

Illinois State Board of Education

100 North First Street • Springfield, Illinois 62777-0001 www.isbe.net

Darren Reisberg *Chair of the Board* **Dr. Carmen I. Ayala** State Superintendent of Education

<u>M E M O R A N D U M</u>

TO:	The Honorable JB Pritzker, Governor The Honorable Jim Durkin, House Minority Leader The Honorable Don Harmon, Senate President
	The Honorable Dan McConchie, Senate Minority Leader
FROM:	The Honorable Emanuel "Chris" Welch, Speaker of the House Dr. Carmen I. Ayala
	State Superintendent of Education
DATE:	September 23, 2021
SUBJECT	The Program and Administration of Undesignated Onioid Antagonis

SUBJECT: The Program and Administration of Undesignated Opioid Antagonist Report, School Year 2020-21

The Program and Administration of Undesignated Opioid Antagonist Report, School Year 2019-20 pursuant to Section 22-30 of the Illinois School Code [105 ILCS 5/22-30]. This report summarizes the characteristics of cases and dosage of undesignated Opioid Antagonist administration reported to the Illinois State Board of Education during the 2020-21 school year. A summary of the major findings:

• ISBE received zero reports of use for undesignated opioid antagonist during the 2020-21 school year.

This report is transmitted on behalf of the State Superintendent of Education. For additional copies of this report or for more specific information, please contact Amanda Elliott, Executive Director, Legislative Affairs at (217) 782-6510 or aelliott@isbe.net.

cc: Secretary of the Senate Clerk of the House Legislative Research Unit State Government Report Center

The Administration of Opioid Antagonist

School Year 2020-21

Illinois State Board of Education

Center for Safe and Healthy Climate

Wellness Department

September 2021

Darren Reisberg, Chairman State Board of Education Dr. Carmen I. Ayala State Superintendent of Education

Table of Contents

Foreword	1
Background	1
Methodology	1
Limitations	1- 2
School Year 2020-21 Results	2

Foreword

The administration of an antidote (antagonist) from a stock supply for an overdose of an opioidcontaining drug to persons who may be experiencing an overdose is permitted according to Illinois School Code (105 ILCS 5/22-30). The Act requires a report form to be provided to the Illinois State Board of Education (ISBE) by each Illinois public and nonpublic school that administers a dose under this Act. This report is to be provided to ISBE within three days of the incident that necessitated use of the antidote drug.

This report document is a compilation of data on the frequency and circumstances of opioid antidote administration during the preceding academic year. The report is provided based on the available data and do not necessarily reflect the official position or policy of ISBE.

Inquiries regarding this report may be directed to Rebecca Doran at <u>rdoran@isbe.net</u> or Theresa Zumba at <u>tzumba@isbe.net</u> in the ISBE Wellness Department. They also can be contacted by calling (217) 782-5270.

Background

Any Illinois school may obtain a medical order for one or more doses of a drug that is intended to reverse an overdose from an opioid-containing drug. The antidote most often is naloxone, delivered either by injection or nasal inhalation. Schools may maintain a supply of the drug and have trained personnel to recognize and respond to an overdose of an opioid drug. By October 1 every year, the Board shall submit an annual report to the General Assembly and publish the report online on the same day of its submission. This particular report summarizes the data reported to ISBE during the 2020-21 school year.

Methodology

Data collection instruments and procedures used by schools to report data on the use of an opioid antidote were developed by ISBE staff in the Wellness, Data Analysis, and Rules Departments and incorporated into rules in accordance with the formal rules process (rule 1.540, <u>https://www.isbe.net/Documents/ONEARK.pdf</u>).

The 2020-21 data collection was conducted using the form "Undesignated Opioid Antagonist Reporting Form" (ISBE 34-20A) <u>https://www.isbe.net/Documents/34-20A-opioid-rptg.pdf#search=34%2D20a%20form</u>

Schools were to email the forms to <u>opioid@isbe.net</u>, which is an email account accessible by Data Analysis, and Wellness staff.

Limitations

The enforcement of the reporting requirement of this Act continues for the school year 2020-21, ending June 30, 2021.

- The validity of the data reported is subject to the limitations of the online report collection.
- A statewide declaration of emergency related to a pandemic impacted a number of schools holding in-person classes and having students, families, and personnel on school grounds during the 2020-21 school year.
- Because no school or district is required to have adopted a policy and procedure for the administration of an opioid antagonist, it is not known how many districts or schools have the policy and procedure in place but did not have an incident requiring the use of drug.

School Year 2020-21 Results

During 2020-21 school year, there were no reports of administering undesignated opioid antagonist in schools for the state.